PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31177627-7	2020	METHODS: Pgp activity was measured as verapamil-sensitive 3 H-digoxin flux.	Digoxin	62-69	phosphoglycolate phosphatase	Homo sapiens	9-12	
31540689-7	2019	Similar 17beta-estradiol-induced expression of P-gp was also detected in cultured human tubular epithelial cells, accompanied by the enhancement of its transport activity of digoxin.	Digoxin	174-181	phosphoglycolate phosphatase	Homo sapiens	47-51	
31540689-8	2019	The present findings suggest the contribution of estradiol to female-predominant expression of P-gp in renal cells, which is associated with sex-related disparities in the renal elimination of digoxin.	Digoxin	193-200	phosphoglycolate phosphatase	Homo sapiens	95-99	
26652279-3	2015	Biodegradable digoxin-loaded PEGylated poly(lactic-co-glycolic acid) nanoparticles may increase digoxin transport across BeWo b30 cell monolayers (an in vitro model of trophoblast in human placenta) by reducing the drug"s interaction with P-gp.	Digoxin	14-21	phosphoglycolate phosphatase	Homo sapiens	239-243	
30238965-0	2018	Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P-gp Inhibition.	Digoxin	25-32	phosphoglycolate phosphatase	Homo sapiens	92-96	
27557477-8	2017	The addition of IL-6 did not change efflux transport of rebamipide even though efflux transport of digoxin, a typical substrate of P-gp, was significantly decreased by the addition of IL-6, indicating decrease of the function of P-gp.	Digoxin	99-106	phosphoglycolate phosphatase	Homo sapiens	131-135	
27557477-8	2017	The addition of IL-6 did not change efflux transport of rebamipide even though efflux transport of digoxin, a typical substrate of P-gp, was significantly decreased by the addition of IL-6, indicating decrease of the function of P-gp.	Digoxin	99-106	phosphoglycolate phosphatase	Homo sapiens	229-233	
30091221-0	2018	PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.	Digoxin	139-146	phosphoglycolate phosphatase	Homo sapiens	27-31	
29709579-2	2018	In this study we measured the inhibitory behaviour of a set of known drugs towards P-gp by using three different probe substrates (digoxin, Hoechst 33,342 and rhodamine 123).	Digoxin	131-138	phosphoglycolate phosphatase	Homo sapiens	83-87	
27720954-1	2016	In this present study, the secretory transport of P-gp substrates, rhodamine 123 and digoxin, was evaluated using a Caco-2/HT29-MTX co-culture characterized by an efflux mechanism and a paracellular permeability closer to the human intestinal barrier compared to the Caco-2 monolayer gold standard.	Digoxin	85-92	phosphoglycolate phosphatase	Homo sapiens	50-54	
27452443-2	2016	Investigations on P-gp regulation in placenta of women with different pregnant pathological states are of great significance to individualized transplacental digoxin treatment for fetal heart failure (FHF).	Digoxin	158-165	phosphoglycolate phosphatase	Homo sapiens	18-22	
26652279-5	2015	P-gp inhibition also increased the permeability of digoxin, but not digoxin-loaded nanoparticles.	Digoxin	51-58	phosphoglycolate phosphatase	Homo sapiens	0-4	
23976943-0	2013	Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.	Digoxin	24-31	phosphoglycolate phosphatase	Homo sapiens	53-57	
25342921-1	2014	INTRODUCTION: The potential for ezogabine/retigabine (EZG/RTG) and its N-acetyl metabolite (NAMR) to inhibit the transporter protein P-glycoprotein-(P-gp)-mediated digoxin transport was tested in vitro.	Digoxin	164-171	phosphoglycolate phosphatase	Homo sapiens	149-153	
25172788-8	2014	RESULTS: Bi-directional transport assay showed that only cryptotanshinone and dihydrotanshinone decreased digoxin efflux ratio in a concentration-dependent manner, indicating their inhibitory effects on P-gp function; whereas, tanshinone I, tanshinone IIA and miltirone had no inhibitory effects.	Digoxin	106-113	phosphoglycolate phosphatase	Homo sapiens	203-207	
24362330-12	2014	CONCLUSION: PMA significantly inhibited P-gp-mediated efflux of digoxin in both Caco-2 and MDCKII-MDR1 cell monolayers via PKC activation.	Digoxin	64-71	phosphoglycolate phosphatase	Homo sapiens	40-44	
23976943-0	2013	Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.	Digoxin	24-31	phosphoglycolate phosphatase	Homo sapiens	138-142	
23976943-1	2013	We have reported that the P-gp substrate digoxin required basolateral and apical uptake transport in excess of that allowed by digoxin passive permeability (as measured in the presence of GF120918) to achieve the observed efflux kinetics across MDCK-MDR1-NKI (The Netherlands Cancer Institute) confluent cell monolayers.	Digoxin	41-48	phosphoglycolate phosphatase	Homo sapiens	26-30	
23976943-1	2013	We have reported that the P-gp substrate digoxin required basolateral and apical uptake transport in excess of that allowed by digoxin passive permeability (as measured in the presence of GF120918) to achieve the observed efflux kinetics across MDCK-MDR1-NKI (The Netherlands Cancer Institute) confluent cell monolayers.	Digoxin	127-134	phosphoglycolate phosphatase	Homo sapiens	26-30	
23976943-3	2013	Therefore, IC50 measurements using digoxin as a probe substrate in this cell line could be due to inhibition of P-gp, of digoxin uptake transport, or both.	Digoxin	35-42	phosphoglycolate phosphatase	Homo sapiens	112-116	
23976943-6	2013	We demonstrate that inhibition of digoxin transport across these cell lines by GF120918, cyclosporine, ketoconazole and verapamil is greater than can be explained by inhibition of P-gp alone.	Digoxin	34-41	phosphoglycolate phosphatase	Homo sapiens	180-184	
23976943-12	2013	We also find that P-gp substrates with relatively low passive permeability such as digoxin, loperamide and vinblastine kinetically require basolateral uptake transport over that allowed by +GF120918 passive permeability, while highly permeable P-gp substrates such as amprenavir, quinidine, ketoconazole and verapamil do not, regardless of whether they actually use the basolateral transporter.	Digoxin	83-90	phosphoglycolate phosphatase	Homo sapiens	18-22	
23976943-12	2013	We also find that P-gp substrates with relatively low passive permeability such as digoxin, loperamide and vinblastine kinetically require basolateral uptake transport over that allowed by +GF120918 passive permeability, while highly permeable P-gp substrates such as amprenavir, quinidine, ketoconazole and verapamil do not, regardless of whether they actually use the basolateral transporter.	Digoxin	83-90	phosphoglycolate phosphatase	Homo sapiens	244-248	
23221528-4	2012	The P-gp inhibitory effect of TSAHC was assessed by [3H]digoxin accumulation in the LLCPK1-MDR1 cell system.	Digoxin	56-63	phosphoglycolate phosphatase	Homo sapiens	4-8	
23684934-6	2013	Digoxin, vinblastine and paclitaxel, established P-gp substrates inhibited transport of NMQ with estimated K(i) values of 250, 0.1 and 0.6 muM, respectively.	Digoxin	0-7	phosphoglycolate phosphatase	Homo sapiens	49-53	
21162698-4	2011	P-gp-mediated efflux of digoxin in Caco-2 cell monolayers was measured in the presence of eribulin.	Digoxin	24-31	phosphoglycolate phosphatase	Homo sapiens	0-4	
20222053-11	2010	These findings may explain the known interaction of telmisartan with digoxin and suggest that it may modulate the bioavailability of drugs whose absorption is restricted by P-gp and possibly also by BCRP or MRP2.	Digoxin	69-76	phosphoglycolate phosphatase	Homo sapiens	173-177	
22028772-9	2011	The P-gp efflux rate constants for quinidine and digoxin were about 3-fold smaller than reported ATP hydrolysis rate constants from P-gp proteoliposomes.	Digoxin	49-56	phosphoglycolate phosphatase	Homo sapiens	4-8	
22028772-9	2011	The P-gp efflux rate constants for quinidine and digoxin were about 3-fold smaller than reported ATP hydrolysis rate constants from P-gp proteoliposomes.	Digoxin	49-56	phosphoglycolate phosphatase	Homo sapiens	132-136	
17827785-3	2007	It has been reported that AMD and N-monodesethylamiodarone (DEA), the active metabolite of AMD, inhibit the P-glycoprotein (P-gp/MDR1)-mediated digoxin transport.	Digoxin	144-151	phosphoglycolate phosphatase	Homo sapiens	124-128	
20091240-5	2010	The apical-to-basolateral (A-to-B) transport of digoxin, a P-gp substrate, was significantly increased by the addition of AS extract in a concentration-dependent manner.	Digoxin	48-55	phosphoglycolate phosphatase	Homo sapiens	59-63	
19414624-6	2009	The transport of [(3)H]digoxin, the P-glycoprotein (P-gp) substrate, after treatment with 100 nM 1,25(OH)(2)D(3) for 3 days revealed a higher apparent permeability (P(app)) value in the basal (B)-to-apical (A) direction over that of vehicle treatment (15.1 +/- 0.53 x 10(-6) versus 11.8 +/- 0.58 x 10(-6) cm/s; P < 0.05), whereas the P(app) in the A-to-B direction was unchanged; the efflux ratio was increased (from 5.8 to 8.0).	Digoxin	23-30	phosphoglycolate phosphatase	Homo sapiens	52-56	
19082742-2	2008	Bidirectional studies for digoxin (probe for P-gp substrate) were performed with and without test compounds (at 10 microM).	Digoxin	26-33	phosphoglycolate phosphatase	Homo sapiens	45-49	
16790532-7	2006	Furthermore, the accumulation of two P-gp substrates, digoxin and saquinavir (an HIV-1 protease inhibitor), was enhanced (1.5- to 1.8-fold) in HIV-1(96ZM651) gp120-treated astrocyte monolayers but was not altered by P-gp inhibitors [e.g., valspodar (PSC833) and elacridar (GF120918)], suggesting a loss of transport activity.	Digoxin	54-61	phosphoglycolate phosphatase	Homo sapiens	216-220	
17377214-3	2007	The aim of the present study was to evaluate the effects of ABCB1 gene polymorphism and P-gp inhibitor co-administration on steady-state digoxin serum concentration in congestive heart failure patients.	Digoxin	137-144	phosphoglycolate phosphatase	Homo sapiens	88-92	
17377214-5	2007	Significant differences were noted in digoxin serum concentrations (C(min,ss)) between patients co-administered and not co-administered P-gp inhibitors: 0.868 +/- 0.348 and 0.524 +/- 0.281 for digoxin (p < 0.002), as well as 1.280 +/- 0.524 and 0.908 +/- 0.358 for methyldigoxin (p < 0.02), respectively.	Digoxin	38-45	phosphoglycolate phosphatase	Homo sapiens	136-140	
17063398-11	2006	Sinomenine (an inhibitor of the p-gp-mediated digoxin efflux) increased paeoniflorin"s bioavailability via the inhibition of p-gp-mediated paeoniflorin efflux in the intestine.	Digoxin	46-53	phosphoglycolate phosphatase	Homo sapiens	32-36	
16790532-7	2006	Furthermore, the accumulation of two P-gp substrates, digoxin and saquinavir (an HIV-1 protease inhibitor), was enhanced (1.5- to 1.8-fold) in HIV-1(96ZM651) gp120-treated astrocyte monolayers but was not altered by P-gp inhibitors [e.g., valspodar (PSC833) and elacridar (GF120918)], suggesting a loss of transport activity.	Digoxin	54-61	phosphoglycolate phosphatase	Homo sapiens	37-41	
16419049-9	2006	These findings suggest that (R)-(+)-citronellal can increase the bioavailability of oral digoxin based on the blockade of P-gp-mediated efflux of digoxin from intestinal epithelia to the lumen in the absorption process.	Digoxin	89-96	phosphoglycolate phosphatase	Homo sapiens	122-126	
16674925-3	2006	Capsaicin at concentrations ranging from 10 to 100 microM, which were found to be non-cytotoxic towards the Caco-2 cells, were observed to inhibit P-gp mediated efflux transport of [3H]-digoxin in the cells.	Digoxin	186-193	phosphoglycolate phosphatase	Homo sapiens	147-151	
16964701-3	2006	Between them, polymorphisms of MDR1 gene coding trans-membrane transport glicoprotein P-gp have been reported to affect the outcome of therapy, and was studied for different drugs-digoxin, fexofenadine, etoposid, vincristine, vinblastine, athracyclines and taxans.	Digoxin	180-187	phosphoglycolate phosphatase	Homo sapiens	86-90	
16419049-9	2006	These findings suggest that (R)-(+)-citronellal can increase the bioavailability of oral digoxin based on the blockade of P-gp-mediated efflux of digoxin from intestinal epithelia to the lumen in the absorption process.	Digoxin	146-153	phosphoglycolate phosphatase	Homo sapiens	122-126	
15890377-5	2005	Cellular accumulation of [3H]digoxin was measured in the presence or absence of P-gp inhibitors or test samples.	Digoxin	25-36	phosphoglycolate phosphatase	Homo sapiens	80-84	
10742982-6	1999	Numerous investigations with drugs such as digoxin, etoposide, cyclosporine, vinblastine, Taxol, loperamide, dom-peridone, and ondansteron demonstrate that P-gp has an important role in determining the pharmacokinetics of substrate drugs.	Digoxin	43-50	phosphoglycolate phosphatase	Homo sapiens	156-160	
15207543-7	2004	Inhibition of digoxin efflux transport in presence of the test compounds (P-gp substrates) demonstrated that 96 well cells express adequate amounts of efflux transporters and perform as well as the 12 and 24 well Caco-2 cells.	Digoxin	14-21	phosphoglycolate phosphatase	Homo sapiens	74-78	
14560928-2	2003	Tween 80 increased apical to basolateral permeability of digoxin in Caco-2 cells suggesting that Tween 80 is an in vitro inhibitor of P-gp.	Digoxin	57-64	phosphoglycolate phosphatase	Homo sapiens	134-138	
10213372-8	1999	In addition, CYP3A substrates and inhibitors varied widely in their ability to inhibit the P-gp-mediated transport of digoxin.	Digoxin	118-125	phosphoglycolate phosphatase	Homo sapiens	91-95	
12492608-8	2002	CONCLUSIONS: This lack of effect of the major MDR1 SNPs on digoxin absorption might be explained by saturation of the maximum transport capacity of intestinal Pgp at the dose used.	Digoxin	59-66	phosphoglycolate phosphatase	Homo sapiens	159-162	
10463589-4	1999	Therefore, the potency of a series of 14 P-gp inhibitors was assessed by measuring their inhibition of the transepithelial flux across Caco-2 cells of digoxin, a prototypical P-gp substrate.	Digoxin	151-158	phosphoglycolate phosphatase	Homo sapiens	41-45	
10463589-4	1999	Therefore, the potency of a series of 14 P-gp inhibitors was assessed by measuring their inhibition of the transepithelial flux across Caco-2 cells of digoxin, a prototypical P-gp substrate.	Digoxin	151-158	phosphoglycolate phosphatase	Homo sapiens	175-179	
1360207-4	1992	Since digoxin is considered a prototype for endogenous digitalis-like glycosides, the results also allow for speculation that endogenous digitalis-like glycosides may be the natural substrates for P-gp.	Digoxin	6-13	phosphoglycolate phosphatase	Homo sapiens	197-201	
35000550-9	2021	CC-90001 co-administration increases the AUCt and Cmax 176% and 339% for rosuvastatin (BCRP/OATP1B1/3), 116% and 171% for digoxin (P-gp), and 266% and 321% for nintedanib (CYP3A & P-gp), respectively.6.	Digoxin	122-129	phosphoglycolate phosphatase	Homo sapiens	131-135